Commentary

Podcast

Goy Gives Insights Into the Future Management of Lymphoma and Multiple Myeloma

Dr Goy discusses the impact of CAR T-cell therapy on the lymphoma and multiple myeloma treatment paradigms and his anticipations for the future of hematologic oncology.

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by John Theurer Cancer Center, Hackensack University Medical Center, we had the pleasure of speaking with Andre H. Goy, MD, about developments in lymphoma and multiple myeloma management. Dr Goy is vice president and physician in chief of Oncology Care Transformation Services, as well as chairman and chief physician officer at John Theurer Cancer Center at Hackensack University Medical Center in New Jersey, where he also serves as chief of the Lymphoma Division. He is also the Lydia Pfund Chair for Lymphoma and the academic chairman of Oncology at the Hackensack Meridian School of Medicine, as well as a professor of medicine at Georgetown University in Washington, DC.

In our exclusive interview, Dr Goy discussed the impact of CAR T-cell therapy on the lymphoma and multiple myeloma treatment paradigms and his anticipations for the future of hematologic oncology.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air, sponsored by John Theurer Cancer Center, Hackensack University Medical Center. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss factors to help determine intensive chemotherapy fitness in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss the diagnosis and prevalence of secondary acute myeloid leukemia.
David Samuel Dicapua Siegel, MD
Noa Biran, MD
Noa Biran, MD